Absci Corporation (ABSI) SEC Filings & Earnings Calls

Revenue concentration risk

“Three partners represented 100% of total partner program revenue in Q2 2026.”

Clinical trial risk

“ABS-201 is in Phase 1/2a; failure could significantly impact the company.”

Cash burn risk

“Net cash used in operating activities was $53.9M for 6M 2026, up from $38.7M in prior year.”

Early-stage biotech with no approved products; revenue is minimal ($0.3M) and dependent on partnerships.

“Revenue was $0.3 million for the three months ended June 30, 2026” · word for word

Clinical development risk: ABS-201 is still in Phase 1/2a; proof-of-concept data not expected until H2 2026 or early 2027.

“Absci anticipates reporting interim proof-of-concept data from this study in the second half of 2026 and full proof-of-concept data in early 2027” · word for word

Dilution from equity offering may pressure existing shareholders.

“Issuance of 13,495,277 new shares.”

Clinical trial risk remains; Phase 1 data is early and may not predict later-stage success.

“Interim Phase 1 data; no specific efficacy or safety numbers disclosed in this filing.”

Revenue concentration risk

“During the three months ended March 31, 2026, two partners represented 100% of total partner program revenue.” · word for word

Cash burn / going concern risk

“We have incurred significant losses since inception, we expect to incur losses in the future and we may not be able to generate sufficient revenue to achieve and maintain profitability.” · word for word

Clinical trial risk

“Biologic drug development is inherently uncertain, and it is possible that our technology may not succeed in discovering appropriate product candidates.” · word for word

Clinical trial risk

“Positive results from early preclinical studies or preliminary results from clinical trials of our product candidates are not necessarily predictive of the results of later preclinical studies and any future clinical trials of our product candidates.”

Dependence on key personnel

“The loss of any member of our senior leadership team or our inability to attract and retain highly skilled scientists and business development professionals could adversely affect our business.”

Financing risk

“We will need to raise additional capital to fund our operations, pre-clinical and clinical development of our internally developed programs, and to improve our Integrated Drug Creation platform.”

Major holder exit / loss of institutional support

“Each of the Reporting Persons ceased to be 5% beneficial owners as of April 10, 2026.” · word for word

Major holder exit / loss of institutional support

“Each of the Reporting Persons ceased to be 5% beneficial owners as of April 10, 2026.” · word for word

Preclinical/clinical uncertainty

“Biologic drug development is inherently uncertain, and it is possible that our technology may not succeed in discovering appropriate product candidates.” · word for word

Capital needs

“We will need to raise additional capital to fund our operations, pre-clinical and clinical development of our internally developed programs, and to improve our Integrated Drug Creation platform.” · word for word

Competition

“The markets in which we operate, including those for Integrated Drug Creation platform technology and our Internally Developed Programs, are highly competitive, and if we are unable to compete effectively, our business and prospects could be adversely affected.” · word for word

Dependence on platform

“We are substantially dependent on the successful application of our Integrated Drug Creation platform to identify, design and advance product candidates for our internally developed programs.” · word for word

Clinical trial risk remains high; no revenue yet

“Company is pre-revenue; ABS-201 still in early-stage trials.”

Loss of Chief Innovation Officer may impact R&D pipeline; mitigated by advisory role and new CMO appointment.

“Andreas Busch retired as Chief Innovation Officer; will serve as scientific advisor.”

Clinical-stage biotech with no approved products; pipeline risk.

“Company is clinical-stage; no approved products; pipeline dependent on trial outcomes.”

Net loss increased YoY; cash burn continues.

“Net loss $14.6M vs $7.6M prior year; cash decreased from $203.9M to $167.2M.”

Resolution of milestone payments reduces future contingent payment uncertainty

“Final distribution of Milestone Consideration in full satisfaction of all potential milestone payments”